Published in Mov Disord on January 15, 2007
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol (2011) 1.64
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest (2014) 1.58
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Brain (2015) 1.50
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa. Neuropsychopharmacology (2011) 1.21
The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse (2009) 1.15
Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. J Neural Transm (Vienna) (2011) 1.12
Placebo influences on dyskinesia in Parkinson's disease. Mov Disord (2008) 1.03
Advances in non-dopaminergic treatments for Parkinson's disease. Front Neurosci (2014) 0.93
Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res (2009) 0.92
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic? Psychopharmacology (Berl) (2007) 0.91
Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology (Berl) (2008) 0.90
Levodopa-induced dyskinesias and their management. J Neurol (2008) 0.89
Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci (2012) 0.86
The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res (2013) 0.86
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism. Psychopharmacology (Berl) (2009) 0.86
Parkin promotes degradation of the mitochondrial pro-apoptotic ARTS protein. PLoS One (2012) 0.85
Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front Neural Circuits (2014) 0.84
Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats. ACS Chem Neurosci (2013) 0.84
Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology (2011) 0.84
The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology (Berl) (2007) 0.83
Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia. Parkinsons Dis (2011) 0.82
Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology (2013) 0.82
Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome. Am J Respir Cell Mol Biol (2014) 0.82
Therapy for Parkinson's disease: what is in the pipeline? Neurotherapeutics (2014) 0.81
Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics (2014) 0.80
Multisite intracerebral microdialysis to study the mechanism of L-DOPA induced dopamine and serotonin release in the parkinsonian brain. ACS Chem Neurosci (2013) 0.80
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. J Neural Transm (Vienna) (2011) 0.80
Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations. Front Neurol (2014) 0.79
Potential cellular and regenerative approaches for the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors. Eur J Neurosci (2012) 0.79
Antidepressant-like properties of sarizotan in experimental Parkinsonism. Psychopharmacology (Berl) (2011) 0.79
Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neural Transm (Vienna) (2010) 0.78
Nondopaminergic treatments for Parkinson's disease: current and future prospects. Neurodegener Dis Manag (2016) 0.77
Pharmacological treatment of Parkinson's disease: life beyond dopamine D2/D3 receptors? J Neural Transm (Vienna) (2008) 0.77
The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat. Psychopharmacology (Berl) (2013) 0.77
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. Br J Pharmacol (2014) 0.76
Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat. J Neurochem (2015) 0.76
Emerging approaches in Parkinson's disease - adjunctive role of safinamide. Ther Clin Risk Manag (2016) 0.75
Understanding and prevention of "therapy-" induced dyskinesias. Parkinsons Dis (2012) 0.75
Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships. J Neural Transm (Vienna) (2015) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol (2004) 6.14
Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry (2011) 5.85
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 4.16
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Subthalamic nucleus stimulation in severe obsessive-compulsive disorder. N Engl J Med (2008) 3.52
The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity (2008) 3.50
Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord (2007) 3.48
Photoreceptor layer thinning in idiopathic Parkinson's disease. Mov Disord (2014) 3.36
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 3.05
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord (2004) 2.90
beta-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol (2003) 2.85
New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance. Mov Disord (2004) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Does dopamine still have a leading role in advanced Parkinson's disease after subthalamic stimulation? Stereotact Funct Neurosurg (2008) 2.64
Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2007) 2.62
"Psychogenic movement disorders": they are what they are. Mov Disord (2014) 2.56
Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell (2009) 2.53
Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem (2007) 2.40
Chlorophyll breakdown in senescent Arabidopsis leaves. Characterization of chlorophyll catabolites and of chlorophyll catabolic enzymes involved in the degreening reaction. Plant Physiol (2005) 2.39
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Neuregulin-1/ErbB signaling serves distinct functions in myelination of the peripheral and central nervous system. Neuron (2008) 2.27
The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol (2008) 2.27
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.26
X-ray analysis of residual stress gradients in TiN coatings by a Laplace space approach and cross-sectional nanodiffraction: a critical comparison. J Appl Crystallogr (2013) 2.21
Genome-wide association study confirms BST1 and suggests a locus on 12q24 as the risk loci for Parkinson's disease in the European population. Hum Mol Genet (2010) 2.21
Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord (2004) 2.13
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology (2013) 2.06
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Predictors of outcome in patients with suspected myocarditis. Circulation (2008) 2.03
Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain (2010) 2.01
Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. Mov Disord (2008) 1.98
Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord (2008) 1.97
Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol (2003) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Loss-of-function mutations in HINT1 cause axonal neuropathy with neuromyotonia. Nat Genet (2012) 1.85
Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp (2009) 1.85
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord (2007) 1.85
Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol (2007) 1.84
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
A 5-year experience with cardiopulmonary resuscitation using extracorporeal life support in non-postcardiotomy patients with cardiac arrest. Resuscitation (2012) 1.78
Activated beta-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem Biophys Res Commun (2003) 1.74
Extracorporeal membrane oxygenation for respiratory failure in adults. Curr Opin Crit Care (2012) 1.73
Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms. PLoS One (2010) 1.72
Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA (2004) 1.71
Premature aging of the immune system in children with juvenile idiopathic arthritis. Arthritis Rheum (2008) 1.71
Novel lyssavirus in Natterer's bat, Germany. Emerg Infect Dis (2011) 1.71
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord (2011) 1.70
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. Am J Hum Genet (2011) 1.65
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord (2005) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Chlorophyll Catabolites - Chemical and Structural Footprints of a Fascinating Biological Phenomenon. European J Org Chem (2008) 1.62
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol (2012) 1.61
Prediction of mortality in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation: a prospective observational study. Crit Care (2014) 1.58
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol (2013) 1.56
In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage (2009) 1.56
Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol (2004) 1.55
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med (2003) 1.52
Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. Hepatology (2013) 1.52
The Dionaea muscipula ammonium channel DmAMT1 provides NH₄⁺ uptake associated with Venus flytrap's prey digestion. Curr Biol (2013) 1.51
Lower tidal volume strategy (≈3 ml/kg) combined with extracorporeal CO2 removal versus 'conventional' protective ventilation (6 ml/kg) in severe ARDS: the prospective randomized Xtravent-study. Intensive Care Med (2013) 1.49
Acquisition of neuronal and glial markers by neural crest-derived cells in the mouse intestine. J Comp Neurol (2003) 1.47
Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol (2008) 1.47
Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain (2009) 1.44
Loss of dermatan-4-sulfotransferase 1 (D4ST1/CHST14) function represents the first dermatan sulfate biosynthesis defect, "dermatan sulfate-deficient adducted thumb-clubfoot syndrome". Hum Mutat (2011) 1.44
How much phenotypic variation can be attributed to parkin genotype? Ann Neurol (2003) 1.44
In vivo participation of red chlorophyll catabolite reductase in chlorophyll breakdown. Plant Cell (2007) 1.43
First experience with the ultra compact mobile extracorporeal membrane oxygenation system Cardiohelp in interhospital transport. Interact Cardiovasc Thorac Surg (2011) 1.43
The neuropathology of manganese-induced Parkinsonism. J Neuropathol Exp Neurol (2007) 1.42
Lbx1 acts as a selector gene in the fate determination of somatosensory and viscerosensory relay neurons in the hindbrain. J Neurosci (2007) 1.42
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord (2013) 1.41
Emerging technologies for the detection of rabies virus: challenges and hopes in the 21st century. PLoS Negl Trop Dis (2009) 1.40
Partial splenectomy: uses of error. Lancet (2002) 1.40
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Atypical parkinsonism and Annonaceae consumption in New Caledonia. Mov Disord (2004) 1.39
The pathogenesis of cell death in Parkinson's disease. Neurology (2006) 1.38
Sox2 and Mitf cross-regulatory interactions consolidate progenitor and melanocyte lineages in the cranial neural crest. Development (2012) 1.37
Localization of stimulating electrodes in patients with Parkinson disease by using a three-dimensional atlas-magnetic resonance imaging coregistration method. J Neurosurg (2003) 1.35
Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci (2002) 1.35